 Enzyme Inhibitors
"Enzyme Inhibitors" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction.
| Descriptor ID |
D004791
|
| MeSH Number(s) |
D27.505.519.389
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Enzyme Inhibitors".
Below are MeSH descriptors whose meaning is more specific than "Enzyme Inhibitors".
This graph shows the total number of publications written about "Enzyme Inhibitors" by people in this website by year, and whether "Enzyme Inhibitors" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 0 | 1 | 1 | | 1995 | 3 | 4 | 7 | | 1996 | 5 | 13 | 18 | | 1997 | 6 | 20 | 26 | | 1998 | 3 | 16 | 19 | | 1999 | 9 | 17 | 26 | | 2000 | 6 | 27 | 33 | | 2001 | 10 | 38 | 48 | | 2002 | 13 | 46 | 59 | | 2003 | 11 | 37 | 48 | | 2004 | 9 | 34 | 43 | | 2005 | 9 | 21 | 30 | | 2006 | 8 | 18 | 26 | | 2007 | 13 | 15 | 28 | | 2008 | 10 | 20 | 30 | | 2009 | 10 | 21 | 31 | | 2010 | 9 | 18 | 27 | | 2011 | 11 | 11 | 22 | | 2012 | 11 | 20 | 31 | | 2013 | 4 | 16 | 20 | | 2014 | 10 | 16 | 26 | | 2015 | 6 | 14 | 20 | | 2016 | 7 | 11 | 18 | | 2017 | 4 | 4 | 8 | | 2018 | 6 | 5 | 11 | | 2019 | 2 | 9 | 11 | | 2020 | 3 | 2 | 5 |
To return to the timeline, click here.
Below are the most recent publications written about "Enzyme Inhibitors" by people in Profiles.
-
Izmirly P, Kim M, Friedman DM, Costedoat-Chalumeau N, Clancy R, Copel JA, Phoon CKL, Cuneo BF, Cohen RE, Robins K, Masson M, Wainwright BJ, Zahr N, Saxena A, Buyon JP. Hydroxychloroquine to Prevent Recurrent Congenital Heart Block in Fetuses of Anti-SSA/Ro-Positive Mothers. J Am Coll Cardiol. 2020 07 21; 76(3):292-302.
-
Doria A, Galecki AT, Spino C, Pop-Busui R, Cherney DZ, Lingvay I, Parsa A, Rossing P, Sigal RJ, Afkarian M, Aronson R, Caramori ML, Crandall JP, de Boer IH, Elliott TG, Goldfine AB, Haw JS, Hirsch IB, Karger AB, Maahs DM, McGill JB, Molitch ME, Perkins BA, Polsky S, Pragnell M, Robiner WN, Rosas SE, Senior P, Tuttle KR, Umpierrez GE, Wallia A, Weinstock RS, Wu C, Mauer M. Serum Urate Lowering with Allopurinol and Kidney Function in Type 1 Diabetes. N Engl J Med. 2020 06 25; 382(26):2493-2503.
-
Zuhra K, Augsburger F, Majtan T, Szabo C. Cystathionine-ß-Synthase: Molecular Regulation and Pharmacological Inhibition. Biomolecules. 2020 04 30; 10(5).
-
Tap WD, Villalobos VM, Cote GM, Burris H, Janku F, Mir O, Beeram M, Wagner AJ, Jiang L, Wu B, Choe S, Yen K, Gliser C, Fan B, Agresta S, Pandya SS, Trent JC. Phase I Study of the Mutant IDH1 Inhibitor Ivosidenib: Safety and Clinical Activity in Patients With Advanced Chondrosarcoma. J Clin Oncol. 2020 05 20; 38(15):1693-1701.
-
Moreira DC, Venkataraman S, Subramanian A, Desisto J, Balakrishnan I, Prince E, Pierce A, Griesinger A, Green A, Eberhardt CG, Foreman NK, Vibhakar R. Targeting MYC-driven replication stress in medulloblastoma with AZD1775 and gemcitabine. J Neurooncol. 2020 May; 147(3):531-545.
-
Stein EM, Fathi AT, DiNardo CD, Pollyea DA, Roboz GJ, Collins R, Sekeres MA, Stone RM, Attar EC, Frattini MG, Tosolini A, Xu Q, See WL, MacBeth KJ, de Botton S, Tallman MS, Kantarjian HM. Enasidenib in patients with mutant IDH2 myelodysplastic syndromes: a phase 1 subgroup analysis of the multicentre, AG221-C-001 trial. Lancet Haematol. 2020 Apr; 7(4):e309-e319.
-
Venkatesan S, Myles PR, Bolton KJ, Muthuri SG, Al Khuwaitir T, Anovadiya AP, Azziz-Baumgartner E, Bajjou T, Bassetti M, Beovic B, Bertisch B, Bonmarin I, Booy R, Borja-Aburto VH, Burgmann H, Cao B, Carratala J, Chinbayar T, Cilloniz C, Denholm JT, Dominguez SR, Duarte PAD, Dubnov-Raz G, Fanella S, Gao Z, Gérardin P, Giannella M, Gubbels S, Herberg J, Higuera Iglesias AL, Hoeger PH, Hu XY, Islam QT, Jiménez MF, Keijzers G, Khalili H, Kusznierz G, Kuzman I, Langenegger E, Lankarani KB, Leo YS, Libster RP, Linko R, Madanat F, Maltezos E, Mamun A, Manabe T, Metan G, Mickiene A, Mikic D, Mohn KGI, Oliva ME, Ozkan M, Parekh D, Paul M, Rath BA, Refaey S, Rodríguez AH, Sertogullarindan B, Skret-Magierlo J, Somer A, Talarek E, Tang JW, To K, Tran D, Uyeki TM, Vaudry W, Vidmar T, Zarogoulidis P, Nguyen-Van-Tam JS. Neuraminidase Inhibitors and Hospital Length of Stay: A Meta-analysis of Individual Participant Data to Determine Treatment Effectiveness Among Patients Hospitalized With Nonfatal 2009 Pandemic Influenza A(H1N1) Virus Infection. J Infect Dis. 2020 01 14; 221(3):356-366.
-
Lomeli BK, Galbraith H, Schettler J, Saviolakis GA, El-Amin W, Osborn B, Ravel J, Hazleton K, Lozupone CA, Evans RJ, Bell SJ, Ochsner UA, Jarvis TC, Baqar S, Janjic N. Multiple-Ascending-Dose Phase 1 Clinical Study of the Safety, Tolerability, and Pharmacokinetics of CRS3123, a Narrow-Spectrum Agent with Minimal Disruption of Normal Gut Microbiota. Antimicrob Agents Chemother. 2019 12 20; 64(1).
-
Wang S, Denton KE, Hobbs KF, Weaver T, McFarlane JMB, Connelly KE, Gignac MC, Milosevich N, Hof F, Paci I, Musselman CA, Dykhuizen EC, Krusemark CJ. Optimization of Ligands Using Focused DNA-Encoded Libraries To Develop a Selective, Cell-Permeable CBX8 Chromodomain Inhibitor. ACS Chem Biol. 2020 01 17; 15(1):112-131.
-
García-Arroyo FE, Monroy-Sánchez F, Muñoz-Jiménez I, Gonzaga G, Andrés-Hernando A, Zazueta C, Juárez-Rojas JG, Lanaspa MA, Johnson RJ, Sánchez-Lozada LG. Allopurinol Prevents the Lipogenic Response Induced by an Acute Oral Fructose Challenge in Short-Term Fructose Fed Rats. Biomolecules. 2019 10 11; 9(10).
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|